论文信息 - Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes - 字舞流文

Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes

K. Pradhan | A. Verma | U. Steidl | A. Cleverly | A. Giagounidis | A. Chiang | U. Platzbecker | V. Santini | B. Will | T. Bhagat | R. Komrokji | I. Gueorguieva | M. Lahn | S. Guba | Yumin Zhao | J. Janssen | D. Valcárcel | A. Sridharan | A. Girvan | Mariana da Silva Ferreira